MYC and B-cell non-Hodgkin lymphoma: This enzyme could contribute to the gain of chromosomal aberrations that affect cell cycle-regulator genes, such as c-MYC; acting together, these mechanisms could lead to the development of aggressive B-cell lymphomas in HIV+ patients (8, 36).